Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Issue : The Pharmaceutical Journal, 9/16 August 2014, Vol 293, No 7822/3

Sort by: Newest first Oldest first A-Z Z-A

  • High-power view of nodular mantle cell lymphoma

    Rare blood cancer treatments recommended for approval by the EMA

    31 JUL 2014 13:17 By Elizabeth Sukkar

    The European Medicines Agency has approved two new medicines, ibrutinib (Janssen-Cilag’s Imbruvica) and idelalisib (Gilead Science’s Zydelig), for adult patients with rare blood cancers.

  • A safe service does not mean it is a good service Subscription

    7 AUG 2014 10:15

    “Surely pharmacists should have been consulted?” writes Graham Phillips (2014;293:85) in his blog about the new General Pharmaceutical Council (GPhC) inspection model for community pharmacies. He considers it unjustified to conclude that only 1 in 30 pharmacies in the UK is “good”. In fact, pharmacists were consulted. I was on the

  • Adverse reactions for Roche's Herceptin Subscription

    5 AUG 2014 12:16

    Nasopharyngitis, thrombocytopenia, weight loss, anorexia, insomnia, paraesthesia, dysgeusia, stomatitis, palmar-plantar erythrodysesthesia syndrome and peripheral oedema are now listed as very common adverse reactions on the summary of product characteristics for Roche’s Herceptin (trastuzumab). Pleural effusion, pharyngitis and pneumonia are now listed as common adverse reactions.

  • Anafranil overdose Subscription

    5 AUG 2014 15:16

    The summary of product characteristics for Anafranil (clomipramine hydrochloride; Novartis) slow-release tablets 75mg now states that rare cases of pharmacobezoar, of varying severity including fatal outcome, have been reported in association with overdose of sustained release Anafranil. Further information about the pharmacobezoar is available in the updated SPC.

  • Anopheles minimus, mosquito causing malaria

    Artemisinin-resistant malaria ‘widespread’ in Southeast Asia

    1 AUG 2014 14:40 By Joanna Lyford

    Researchers call for radical measures to prevent resistance to the most effective type of antimalarial agent spreading to the Indian subcontinent and beyond.

  • AWMSG decisions Subscription

    5 AUG 2014 10:13

    The following medicines have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG): eltrombopag to treat thrombocytopenia in adults with hepatitis C infection where the degree of thrombocytopenia is compromising the efficacy of interferon; imatinib for adjuvent treatment of KIT-positive gastrointestinal stromal tumours; Eviplera (emtricitabine, rilpivirine and tenofovir; Gilead) for treatment-experienced adults infected with HIV type 1; and velaglucerase ...

  • Berwick report messages remain relevant a year on

    7 AUG 2014

    The lessons from Mid Staffs should resonate beyond England and more widely than hospital care.

  • Zameer Choudrey, CEO of Bestway Group

    Bestway aims high in the UK pharmacy market

    5 AUG 2014 20:30 By Elizabeth Sukkar

    How will Bestway, new owner of the UK’s third largest pharmacy chain, perform in the pharmacy market? And, crucially, will it change the Co-operative business model?

  • Bonviva tablets discontinued Subscription

    5 AUG 2014 9:36

    Roche has discontinued Bonviva (ibandronic acid) tablets 150mg x 3. The single tablet packs and the pre-filled syringe 3mg/ml will continue to be available. Medical information on 0800 328 1629.

  • Buccolam oromucosal solution recall Subscription

    5 AUG 2014 12:02

    The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a medicines recall for specific batches of ViroPharma’s Buccolam oromucosal solution (midazolam hydrochloride). This is because a routine inspection of the company’s contract manufacturing site in the UK identified the possibility of chemical contamination. Further information is available from the

Show  10 per page20 per page50 per page

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.